AR029096A1 - COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELINE AND A COMPOUND OF OPIOID EFFECT, MEDICATIONS AND MEDICINAL FORMULATIONS CONTAINING SUCH COMBINATION AND ITS USE FOR THE PREPARATION OF MEDICATIONS FOR PAIN TREATMENT - Google Patents

COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELINE AND A COMPOUND OF OPIOID EFFECT, MEDICATIONS AND MEDICINAL FORMULATIONS CONTAINING SUCH COMBINATION AND ITS USE FOR THE PREPARATION OF MEDICATIONS FOR PAIN TREATMENT

Info

Publication number
AR029096A1
AR029096A1 ARP010102403A ARP010102403A AR029096A1 AR 029096 A1 AR029096 A1 AR 029096A1 AR P010102403 A ARP010102403 A AR P010102403A AR P010102403 A ARP010102403 A AR P010102403A AR 029096 A1 AR029096 A1 AR 029096A1
Authority
AR
Argentina
Prior art keywords
combination
medications
active substances
compound
preparation
Prior art date
Application number
ARP010102403A
Other languages
Spanish (es)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR029096A1 publication Critical patent/AR029096A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinacion de sustancias activas que contiene montirelina y un compuesto de efecto opioide y/o una de sus sales fisiologicamente tolerables, medicamentos que contiene esta combinacion de sustancias activas, formulacion medicamentosa que contien e esta combinacion de sustancias activas, así como el uso de la combinacion de sustancias activas para la preparacion de un medicamento para el tratamiento del dolor.A combination of active substances containing montirelin and a compound with an opioid effect and / or one of its physiologically tolerable salts, medicines containing this combination of active substances, drug formulation containing this combination of active substances, as well as the use of combination of active substances for the preparation of a medication for the treatment of pain.

ARP010102403A 2000-05-26 2001-05-21 COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELINE AND A COMPOUND OF OPIOID EFFECT, MEDICATIONS AND MEDICINAL FORMULATIONS CONTAINING SUCH COMBINATION AND ITS USE FOR THE PREPARATION OF MEDICATIONS FOR PAIN TREATMENT AR029096A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10025947A DE10025947A1 (en) 2000-05-26 2000-05-26 Active ingredient combination containing montirelin and a compound with opioid activity

Publications (1)

Publication Number Publication Date
AR029096A1 true AR029096A1 (en) 2003-06-04

Family

ID=7643551

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102403A AR029096A1 (en) 2000-05-26 2001-05-21 COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELINE AND A COMPOUND OF OPIOID EFFECT, MEDICATIONS AND MEDICINAL FORMULATIONS CONTAINING SUCH COMBINATION AND ITS USE FOR THE PREPARATION OF MEDICATIONS FOR PAIN TREATMENT

Country Status (5)

Country Link
AR (1) AR029096A1 (en)
AU (1) AU2001274020A1 (en)
DE (1) DE10025947A1 (en)
PE (1) PE20011272A1 (en)
WO (1) WO2001091733A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
NZ602075A (en) * 2010-02-24 2014-01-31 Cima Labs Inc Abuse-resistant formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant

Also Published As

Publication number Publication date
AU2001274020A1 (en) 2001-12-11
DE10025947A1 (en) 2001-11-29
PE20011272A1 (en) 2002-01-26
WO2001091733A2 (en) 2001-12-06
WO2001091733A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
ATE509616T1 (en) TOPICAL PHARMACEUTICAL AND/OR COSMETIC DOSAGE SYSTEMS
AR033423A1 (en) PHARMACEUTICAL SALTS CONSTITUTED OF AN ACTIVE PHARMACEUTICAL SUBSTANCE AND AT LEAST A SWEETENER, MEDICATIONS CONTAINING THESE SALTS AND USE OF THESE SALTS FOR THE PREPARATION OF MEDICINES
AR039744A1 (en) METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION
AR004391A1 (en) CONTROLLED RELEASE FORMULATION FOR BASIC PHARMACS SLIMMY SOLUBLE.
UY27908A1 (en) FORMULATIONS AND DOSAGE FORMS FOR THE CONTROLLED ADMINISTRATION OF TOPIRAMATO
CR7362A (en) PHARMACEUTICAL FORMULATIONS OF PLATINUM DERIVATIVE
EE9900288A (en) Use of an Oral Pharmaceutical Composition for the manufacture of a medicament for the treatment of erectile dysfunction in men
BR0306513A (en) medicine buffer
BRPI0406486A (en) Fluid drug delivery device
AR030253A1 (en) DRUG SUPPLY SYSTEMS FOR EXEMPTIONALLY INSOLUBLE LIPOFILIC DRUGS IN WATER, A FORMULATION AND THE USE OF A COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR018862A1 (en) PHARMACEUTICAL FORMULATION OF PROLONGED RELEASE, IMPROVED FOR THE ORAL ADMINISTRATION OF NEFAZODONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME; ORAL DOSAGE FORM THAT UNDERSTANDS AND USE OF SUCH FORMULATION TO PREPARE THE SUCH DOSAGE FORM
ATE292453T1 (en) ANTIVIRAL DRUG
AR013967A1 (en) A DRUG FORMULATION FOR ORAL ADMINISTRATION OF CONTROLLED PELLET PELLET THAT HAS CONTROLLED RELEASE OF AN ACTIVE COMPOUND THAT IS SELECTED FROM THE ACID 1-CYCLOPROPIL-7- [(S, S) -2,8-DIAZABICICLO [4.3.0] NON- 8-IL] -6-FLUOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-CARBOXILIC QUINOLON OR SALE
AR034813A1 (en) PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
CR7049A (en) EMPLOYMENT OF FLUMAZENYL IN THE DEVELOPMENT OF A MEDICATION FOR THE TREATMENT OF ALCOHOL DEPENDENCE
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
ATE262893T1 (en) DOSAGE FORMS FOR THE TREATMENT OF ORAL MYCOSES
BRPI0607172A2 (en) method for administering at least one pharmaceutically active substance to a patient, combining medicaments and using at least one pharmaceutically active substance for the manufacture of a combination of medicaments
AR036877A1 (en) PHARMACEUTICAL FORMULATION
PE20030830A1 (en) AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL
CL2004001843A1 (en) COMBINATION OF (A) AT LEAST A 2,5-DIHYDROBENCENOSULPHONIC DERIVATIVE, AS CALCIUM DOBEYLATE, ETHAMSYLATE AND PERSILATE, AND (B) AT LEAST A MODULATOR OF POTASSIUM CHANNELS, PHARMACEUTICAL COMPOSITION CONTAINING AND USE AS A MEDICATION IN PROFILA
AR029096A1 (en) COMBINATION OF ACTIVE SUBSTANCES CONTAINING MONTIRELINE AND A COMPOUND OF OPIOID EFFECT, MEDICATIONS AND MEDICINAL FORMULATIONS CONTAINING SUCH COMBINATION AND ITS USE FOR THE PREPARATION OF MEDICATIONS FOR PAIN TREATMENT
BRPI0416415A (en) medicine in the form of an orally administered film and use of at least one cholinergic active substance acting on the central nervous system
AR042308A1 (en) DRUG AND TRANSMUCOSICAL ADMINISTRATION MEDICINAL WITH IMPROVED ABSORPTION OF ACTIVE PRINCIPLES
AR031846A1 (en) COMBINATION OF ACTIVE SUBSTANCES, MEDICATIONS AND FORMULATIONS THAT CONTAIN IT, AND USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PAIN

Legal Events

Date Code Title Description
FB Suspension of granting procedure